Disease classification: measuring the effect of the Tenth Revision of the International Classification of Diseases on cause-of-death data in the United States

2003 ◽  
Vol 22 (9) ◽  
pp. 1551-1570 ◽  
Author(s):  
Robert N. Anderson ◽  
Harry M. Rosenberg
Keyword(s):  
United States ◽  
Cause Of Death ◽  
International Classification Of Diseases ◽  
The United States ◽  
International Classification ◽  
Disease Classification ◽  
Classification Of Diseases ◽  
Death Data

scholarly journals A narrative review of the impact of the transition to ICD-10 and ICD-10-CM/PCS

JAMIA Open ◽  
2019 ◽  
Vol 3 (1) ◽  
pp. 126-131 ◽  
Author(s):  
Sheila V Kusnoor ◽  
Mallory N Blasingame ◽  
Annette M Williams ◽  
Spencer J DesAutels ◽  
Jing Su ◽  
...  
Keyword(s):  
United States ◽  
International Classification Of Diseases ◽  
The United States ◽  
International Classification ◽  
Morbidity And Mortality ◽  
Classification Of Diseases ◽  
Icd 10 ◽  
The Impact ◽  
Mortality Surveillance

Abstract Objectives The United States transitioned to the tenth version of the International Classification of Diseases (ICD) system (ICD-10) for mortality coding in 1999 and to the International Classification of Diseases, Clinical Modification and Procedure Coding System (ICD-10-CM/PCS) on October 1, 2015. The purpose of this study was to conduct a narrative literature review to better understand the impact of the implementation of ICD-10/ICD-10-CM/PCS. Materials and Methods We searched English-language articles in PubMed, Web of Science, and Business Source Complete and reviewed websites of relevant professional associations, government agencies, research groups, and ICD-10 news aggregators to identify literature on the impact of the ICD-10/ICD-10-CM/PCS transition. We used Google to search for additional gray literature and used handsearching of the references of the most on-target articles to help ensure comprehensiveness. Results Impact areas reported in the literature include: productivity and staffing, costs, reimbursement, coding accuracy, mapping between ICD versions, morbidity and mortality surveillance, and patient care. With the exception of morbidity and mortality surveillance, quantitative studies describing the actual impact of the ICD-10/ICD-10-CM/PCS implementation were limited and much of the literature was based on the ICD-10-CM/PCS transition rather than the earlier conversion to ICD-10 for mortality coding. Discussion This study revealed several gaps in the literature that limit the ability to draw reliable conclusions about the overall impact, positive or negative, of moving to ICD-10/ICD-10-CM/PCS in the United States. Conclusion These knowledge gaps present an opportunity for future research and knowledge sharing and will be important to consider when planning for ICD-11.

Perspectives on the International Classification of Diseases, 11th Revision, developments in allergy clinical practice in the United States

2017 ◽  
Vol 118 (2) ◽  
pp. 127-132 ◽  
Author(s):  
Luciana Kase Tanno ◽  
James L. Sublett ◽  
J. Allen Meadows ◽  
Moises Calderon ◽  
Garry N. Gross ◽  
...  
Keyword(s):  
United States ◽  
Clinical Practice ◽  
International Classification Of Diseases ◽  
The United States ◽  
International Classification ◽  
Classification Of Diseases

scholarly journals International Analysis of Age-Specific Mortality Rates From Mesothelioma on the Basis of the International Classification of Diseases, 10th Revision

2018 ◽  
pp. 1-15 ◽  
Author(s):  
Paolo Boffetta ◽  
Matteo Malvezzi ◽  
Enrico Pira ◽  
Eva Negri ◽  
Carlo La Vecchia
Keyword(s):  
United States ◽  
Age Groups ◽  
International Classification Of Diseases ◽  
The United States ◽  
Mortality Rates ◽  
International Classification ◽  
Peritoneal Mesothelioma ◽  
Specific Mortality ◽  
Classification Of Diseases

Past analyses of mortality data from mesothelioma relied on unspecific codes, such as pleural neoplasms. We calculated temporal trends in age-specific mortality rates in Canada, the United States, Japan, France, Germany, Italy, the Netherlands, Poland, the United Kingdom, and Australia on the basis of the 10th version of the International Classification of Diseases, which includes a specific code for mesothelioma. Older age groups showed an increase (in the United States, a weaker decrease) during the study period, whereas in young age groups, there was a decrease (in Poland, a weaker increase, starting, however, from low rates). Results were consistent between men and women and between pleural and peritoneal mesothelioma, although a smaller number of events in women and for peritoneal mesothelioma resulted in less precise results. The results show the heterogeneous effect of the reduction of asbestos exposure on different age groups; decreasing mortality in young people reflects reduced exposure opportunity, and increasing mortality in the elderly shows the long-term effect of early exposures.

scholarly journals The Tragedy of the Implementation of ICD-10- CM as ICD-10: Is the Cart Before the Horse or Is There a Tragic Paradox of Misinformation and Ignorance?

2015 ◽  
Vol 18;4 (4;18) ◽  
pp. E485-E495
Author(s):  
Laxmaiah Manchikanti
Keyword(s):  
United States ◽  
Health Insurance ◽  
Health Information ◽  
International Classification Of Diseases ◽  
The United States ◽  
International Classification ◽  
Classification Of Diseases ◽  
Icd 10 ◽  
Health Insurance Portability

The forced implementation of ICD-10-CM (International Classification of Diseases, Tenth Revision, Clinical Modification) codes that are specific to the United States, scheduled for implementation October 1, 2015, which is vastly different from ICD-10 (International Classification of Diseases, Tenth Revision), implemented worldwide, which has 14,400 codes, compared to ICD-10-CM with 144,000 codes to be implemented in the United States is a major concern to practicing U.S. physicians and a bonanza for health IT and hospital industry. This implementation is based on a liberal interpretation of the Health Insurance Portability and Accountability Act (HIPAA), which requires an update to ICD-9- CM (International Classification of Diseases, Ninth Revision, Clinical Modification) and says nothing about ICD-10 or beyond. On June 29, 2015, the Supreme Court ruled that the Environmental Protection Agency unreasonably interpreted the Clean Air Act when it decided to set limits on the emissions of toxic pollutants from power plants, without first considering the costs on the industry. Thus, to do so is applicable to the medical industry with the Centers for Medicare and Medicaid Services (CMS) unreasonably interpreting HIPAA and imposing existent extensive regulations without considering the cost. In the United States, ICD-10-CM with a 10-fold increase in the number of codes has resulted in a system which has become so complicated that it no longer compares with any other country. Moreover, most WHO members use the ICD-10 system (not ICD-10-CM) only to record mortality in 138 countries or morbidity in 99 countries. Currently, only 10 countries employ ICD-10 (not ICD-10-CM) in the reimbursement process, 6 of which have a single payer health care system. Development of ICD-10-CM is managed by 4 non-physician groups, known as cooperating parties. They include the Centers for Disease Control and Prevention (CDC), CMS, the American Hospital Association (AHA), and the American Health Information Management Association (AHIMA). The AHIMA has taken the lead with the AHA just behind, both with escalating profits and influence, essentially creating a statutory monopoly for their own benefit. Further, the ICD-10-CM coalition includes 3M which will boost its revenues and profits substantially with its implementation and Blue Cross Blue Shield which has its own agenda. Physician groups are not a party to these cooperating parties or coalitions, having only a peripheral involvement. ICD-10-CM creates numerous deficiencies with 500 codes that are more specific in ICD-9-CM than ICD-10-CM. The costs of an implementation are enormous, along with maintenance costs, productivity, and cash disruptions. Key words: ICD-10-CM, ICD-10, ICD-9-CM (International Classification of Diseases, 10th Revision, Ninth revision, Clinical Modification), Health Insurance Portability and Accountability Act (HIPAA), Health Information Technology (HIT), costs of implementation

The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United States

2018 ◽  
Vol 4 (1) ◽  
pp. 77-78
Author(s):  
Timothy Beukelman ◽  
Fenglong Xie ◽  
Ivan Foeldvari
Keyword(s):  
United States ◽  
Systemic Sclerosis ◽  
Claims Data ◽  
International Classification Of Diseases ◽  
The United States ◽  
Administrative Claims ◽  
Administrative Claims Data ◽  
Diagnosis Codes ◽  
Classification Of Diseases

Juvenile localised scleroderma is believed an orphan autoimmune disease, which occurs 10 times more often than systemic sclerosis in childhood and is believed to have a prevalence of 1 per 100,000 children. To gain data regarding the prevalence of juvenile localised scleroderma, we assessed the administrative claims data in the United States using the International Classification of Diseases, Ninth Revision diagnosis codes. We found an estimated prevalence in each year ranging from 3.2 to 3.6 per 10,000 children. This estimate is significantly higher as found in previous studies.

scholarly journals Trends in the Treatment of Dupuytren Disease in the United States Between 2007 and 2014

Hand ◽  
2016 ◽  
Vol 12 (1) ◽  
pp. 13-20 ◽  
Author(s):  
Marc D. Lipman ◽  
Samuel Evan Carstensen ◽  
Dylan Nicole Deal
Keyword(s):  
United States ◽  
Treatment Options ◽  
International Classification Of Diseases ◽  
The United States ◽  
Classification Of Diseases ◽  
And Gender ◽  
Needle Aponeurotomy ◽  
Gender Change ◽  
Dupuytren Disease

Background: Dupuytren disease is a common fibroproliferative disorder. Multiple procedural treatment options are available, with Collagenase Clostridium Histolyticum (CCH) injection being introduced in 2010. The purpose of this study was to investigate trends in the treatment of Dupuytren disease in the United States between 2007 and 2014. Methods: The PearlDiver Humana database was queried using International Classification of Diseases, Ninth Revision (ICD-9) and Current Procedural Terminology (CPT) codes for patients with Dupuytren disease that received percutaneous needle aponeurotomy (PNA), fasciotomy, fasciectomy, and CCH injection. Patients were filtered by age, number of comorbidities, and gender. Change in composition of treatments over time was analyzed for each demographic group between 2007 and 2014. Results: Patients presenting to clinic for Dupuytren disease increased from 1118 to 3280, with unchanging treatment percentage of 41. Percent fasciotomies and fasciectomies decreased from 5% to 3% and 33% to 21%, while CCH injection increased to 11% by 2012 to 2014. Percent fasciotomies decreased ( P < .05) in younger healthier (age <65, 0-1 comorbidities) and older less healthy (age 65-74, 4+ comorbidities) populations. Percent fasciectomies decreased significantly in nearly all age and comorbidity groups, but by greater amounts in patients with 2+ comorbidities with increasing age. Percent CCH injections increased in all groups, at rates similar to the losses seen in open procedures. Conclusions: CCH injections have risen to substantial levels, with corresponding decreases in the percentage of patients receiving fasciotomies and fasciectomies. Patient age, comorbidities, and gender appear to have influence on the treatment chosen, likely due to their effects on surgical risk and the importance of timely return to activity.

Sign in / Sign up

Export Citation Format

Share Document